// App-Quantinova.ai

: High-Dose Idarubicin Plus Busulfan As Conditioning Regimen to Autologous Stem Cell Transplantation Improves Prognosis in Patients with Favorable and Intermediate-Risk AML

Researchers

Presenter

  • Ming Hong

Principal Investigators

  • Wenjie Liu

  • Qian Sun

  • Sixuan Qian

  • Jianyong Li

Medical Centers

  • Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China

  • Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  • Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cytarabine liposomal

  • Idarubicin Hydrochloride

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved